An Indiana company is making significant progress with it’s own coronavirus treatment. Eli Lilly says it’s coronavirus antibody treatment can greatly reduce hospitalizations and deaths for high-risk patients with COVID-19. Lilly says the results of the treatment’s phase three trial show 87-percent reduction in patients who had reactions to coronavirus, compared to a group who did not receive the treatment. The patients that were tested in the trial were people 12 and older who had mild cases of coronavirus.
